Breakthrough Lectures to Headline the 2025 World Congress of Neurology in Seoul
SEOUL, South Korea, Oct. 8, 2025 /PRNewswire/ -- The World Federation of Neurology…
Bus World 2025: CRRC EV Debuts Two All-Electric Buses, Introduces Digital-Intelligent Low-Carbon Urban Transit System to Redefine Smarter Urban Mobility
BRUSSELS, Oct. 5, 2025 /PRNewswire/ -- CRRC Electric Vehicle Co., Ltd. (CRRC EV),…
Trinasolar Vertex N Shield module wins comprehensive reliability award from TV Rheinland
CHANGZHOU, China, Sept. 30, 2025 /PRNewswire/ -- Trinasolar announced its Vertex N…
GAC’s Feng Xingya: User-Centric Green Solutions for a Sustainable Future
GUANGZHOU, China, Sept. 30, 2025 /PRNewswire/ -- At the opening of the…
EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts
PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today…
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
September 09, 2025 11:00 ET | Source: Chiesi Global Rare Diseases Results…
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to…
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint…
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing…